The earnings call highlights Ascendis Pharma's strong launch and revenue growth for YORVIPATH, alongside significant advances in their product pipeline. However, this success is tempered by increased operating expenses and ongoing challenges in securing insurance reimbursements. Overall, the sentiment is balanced with significant achievements and operational challenges.

Company Guidance -

Q3 2025

During the Ascendis Pharma First Quarter 2025 Earnings Conference Call, the company provided guidance on several key metrics and strategic initiatives. For the first quarter ending March 31, 2025, YORVIPATH generated €45 million in revenue, up from €40 million in the previous quarter, with more than 1,750 patients in the U.S. receiving prescriptions from over 1,000 unique prescribers. SKYTROFA, another key product, achieved €51 million in revenue, capturing around 7% of the total U.S. growth hormone market and 43% of the long-acting segment. Ascendis anticipates YORVIPATH will significantly impact its 2025 financial profile, projecting revenue growth as market access expands in Europe. The company is also advancing its TransCon CNP pipeline, with an NDA submission to the FDA in March and an MAA filing expected with EMEA in Q3 2025. Ascendis aims to continue building on its U.S. and European market successes, with strategic plans for clinical trial expansions and regulatory filings to support its growth trajectory.

Successful Launch of YORVIPATH

YORVIPATH, the first and only FDA approved treatment for hypoparathyroidism in adults, was prescribed by over 1,000 unique prescribers for more than 1,750 patients in the U.S. in its first quarter since launch.

Strong Revenue Growth

Total global YORVIPATH revenue grew to €45 million in Q1 2025 from €40 million in Q4 2024. SKYTROFA revenues reached €51 million, capturing 7% of the total U.S. growth hormone market.

Advancement of Pipeline Products

The company submitted an NDA to the FDA for TransCon CNP in March and is planning to file an MAA with EMEA in Q3 2025. TransCon CNP has shown promise in treating achondroplasia.

Positive Financial Position

As of March 31, 2025, Ascendis Pharma had cash and cash equivalents totaling €518 million, supporting continued growth and development.

Ascendis Pharma (ASND) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ASND Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	- / -	-2.005	―	―	―
Aug 07, 2025	2025 (Q2)	-1.50 / -	-2.227	―	―	―
May 01, 2025	2025 (Q1)	-1.71 / -1.84	-2.682	31.30% (+0.84)	―
Feb 12, 2025	2024 (Q4)	-1.15 / -0.75	-1.795	58.44% (+1.05)	―
Nov 14, 2024	2024 (Q3)	-1.82 / -2.01	-3.136	36.06% (+1.13)	―
Sep 03, 2024	2024 (Q2)	-1.70 / -2.23	-2.518	11.57% (+0.29)	―
May 02, 2024	2024 (Q1)	-1.72 / -2.68	-2.308	-16.16% (-0.37)	―
Feb 07, 2024	2023 (Q4)	-2.12 / -1.80	-4.314	58.38% (+2.52)	―
Nov 07, 2023	2023 (Q3)	-2.77 / -3.14	-3.62	13.37% (+0.48)	―
Sep 05, 2023	2023 (Q2)	-2.94 / -2.52	-1.702	-47.95% (-0.82)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ASND Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 01, 2025	$167.47	$172.06	+2.74%
Feb 12, 2025	$126.14	$142.49	+12.96%
Nov 14, 2024	$124.28	$126.51	+1.79%
Sep 03, 2024	$134.68	$119.50	-11.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ascendis Pharma A/S (ASND) report earnings?

Ascendis Pharma A/S (ASND) is schdueled to report earning on Aug 07, 2025, TBA (Confirmed).

What is Ascendis Pharma A/S (ASND) earnings time?

Ascendis Pharma A/S (ASND) earnings time is at Aug 07, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ASND EPS forecast?

ASND EPS forecast for the fiscal quarter 2025 (Q2) is -1.5.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing